Omnicell (OMCL) Q1 EPS Recovery Tests Bullish Margin Improvement Narrative

Omnicell (OMCL) opened 2026 with Q1 revenue of US$309.9 million and basic EPS of US$0.25, alongside trailing twelve month revenue of about US$1.2 billion and EPS of US$0.45 that point to relatively slim profitability. Over the past year, the company has seen quarterly revenue range from US$269.7 million to US$314.0 million and basic EPS swing between a loss of US$0.15 and a profit of US$0.34, while trailing net margins have stayed low and a touch softer than the prior year. For investors, these results keep the focus squarely on how efficiently Omnicell can convert its sizable revenue base into steadier margins.

See our full analysis for Omnicell.

With the latest figures on the table, the next step is to compare these margins and earnings trends with the most common narratives around Omnicell to see which views align with the data and which start to look stretched.

See what the community is saying about Omnicell

Margins Still Thin At 1.7% Net

• Over the last twelve months, Omnicell generated about US$1.2b of revenue and US$20.4 million of net income, which works out to a 1.7% net margin, compared with 1.9% a year earlier.
• Consensus narrative sees the cloud and SaaS shift as a way to support better margins over time. However, the current 1.7% margin and trailing EPS of US$0.45 show that progress is starting from a low base.
  • Supporters point to growing recurring software and services as a buffer for margins, but the recent margin trend in the data is still slightly softer year over year.
  • The tension here is that analysts talk about margin improvement, while the last twelve months in the numbers still sit close to breakeven compared with many other Medical Equipment names.

Revenue Near US$1.2b, Profit Still Volatile

• Trailing twelve month revenue reached about US$1.2b, yet quarterly net income has swung between a loss of US$7.0 million in Q1 2025 and a profit of US$15.8 million in Q4 2024, highlighting how bumpy profitability has been.
• Bulls argue that platform adoption, automation demand, and recurring contracts will support more stable earnings. The last five years of earnings declining around 38.1% per year and the recent quarterly profit swings mean that this optimism is leaning heavily on a change in pattern that is not yet visible in the historical figures.
  • Bullish expectations of roughly 36% yearly earnings growth sit against a track record where year over year earnings in the last twelve months were negative and margins have only hovered around low single digits.
  • For that bullish case to play out, the company would have to turn a very thin and volatile earnings base into something much stronger while managing costs tightly, which the recent numbers have not yet confirmed.

Bulls point to Omnicell's SaaS transition and healthcare automation demand as reasons these swings could settle into stronger growth. If you want to see how that optimistic case is built out in full, check out the 🐂 Omnicell Bull Case

Rich 95.9x P/E Needs Forecasts To Hit

• On a trailing basis, Omnicell trades at a P/E of 95.9x, compared with 63.4x for peers and 24x for the broader US Medical Equipment industry, even though the latest net margin is just 1.7% and five year earnings have declined at about 38.1% per year.
• Bears highlight that this premium valuation leaves little room for missteps, especially with only modest forecast revenue growth of about 4.3% a year and mixed profitability history, so any shortfall against the strong earnings growth forecasts could matter more than usual.
  • The share price of US$43.10 sits above the DCF fair value of about US$49.48 only if that model is treated as a long term anchor, while the very high P/E already assumes that earnings forecasts closer to 36.2% annual growth are met.
  • Critics argue that when a company has a P/E multiple this far above its industry at the same time as slim margins and past earnings declines, the burden of proof is firmly on future results to justify the current price tag.

If you want to see how skeptics frame that valuation risk against Omnicell's growth story, it is worth reading the detailed cautious case in the 🐻 Omnicell Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Omnicell on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

After weighing both bullish and cautious angles, it helps to look past headlines and test the story against the raw numbers yourself. If you want to see what is currently supporting optimism around the stock, take a closer look at the 3 key rewards.

See What Else Is Out There

Omnicell combines a very slim 1.7% net margin, volatile quarterly earnings, and a rich 95.9x P/E, which leaves little cushion if optimistic forecasts fall short.

If that mix of thin profitability and premium pricing feels uncomfortable, compare it with companies screened for stronger value by checking out the 52 high quality undervalued stocks

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com